Recombinant hepatitis A virus and application thereof

CN119331837APending Publication Date: 2025-01-21ACADEMY OF MILITARY MEDICAL SCIENCES
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411278857.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-12
Publication Date
2025-01-21

AI Technical Summary

Technical Problem

The prior art is difficult to replicate efficiently in vitro and simulate liver damage caused by hepatitis A virus infection in vivo, which limits the establishment of the reverse genetics system of hepatitis A virus and related research.

Method used

By mutating the hepatitis A virus genome and replacing amino acids at positions 1052 and 1163, a recombinant hepatitis A virus and its full-length infectious cDNA clone were constructed to achieve efficient replication in vitro and simulate liver damage caused by hepatitis A virus infection in vivo.

Benefits of technology

The efficient replication of the recombinant hepatitis A virus in vitro and the simulation of liver damage caused by hepatitis A virus infection in vivo provide a basis for the establishment of a reverse genetics system for hepatitis A virus and related research.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119331837A_ABST
    Figure CN119331837A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of biology, and discloses a recombinant hepatitis A virus (hepatitis A virus for short) and application thereof. The recombinant hepatitis A virus provided by the invention can be efficiently replicated in vitro, and also can simulate liver injury caused by hepatitis A virus infection in vivo, thereby providing a basis for construction of a reverse genetics system of the hepatitis A virus and related research work.
Need to check novelty before this filing date? Find Prior Art